Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — Investor Presentation (March 2026)
17 slides from Amplia Therapeutics's investor presentation, March 2026
Slide 1: Investor Webinar
Investor Webinar MARCH 2026 Dr Chris Burns Dr Rhiannon Jones CEO and MD COO ampliatx.com | @ampliatx ASX: ATX | OTCQB: INNMF
Slide 2: Disclaimer
2 Disclaimer This presentation (Presentation) contains summary information about Amplia Therapeutics Limited ACN Forward-looking statements are based on the Company’s good faith assumptions as to the financial 165 160 841 and its subsidiaries (the Company or Amplia) which is current as at 31 Decembe
Slide 3: Pancreatic Cancer
3 Pancreatic Cancer rd $3.8b 3 Global market predicted to grow most common to $14.4b by 2034* cause cancer death 3% 5 year survival rate for advanced disease *USD; Fortune Business Insights March 2026
Slide 4: Pancreatic cancer is harder to treat due to a fibrotic barrier
4 Pancreatic cancer is harder to treat due to a fibrotic barrier Chemotherapy NARMAFOTINIB Cancer Associated Fibroblasts Narmafotinib acts to reduce Both narmafotinib produce a dense fibrous the fibrous tissue thus and the chemotherapy matrix that surrounds the allowing chemotherapy and can act dire
Slide 5: Narmafotinib: Makes other drugs work better
5 05 NARMAFOTINIB Makes other drugs work better
Slide 6: Narmafotinib: Efficacy, Tolerability, Durability, Convenience
6 Narmafotinib Efficacy Tolerability Durability Convenience
Slide 7: ACCENT Trial
7 ACCENT Trial Narmafotinib + gemcitabine and Abraxane (G/A) in metastatic pancreatic cancer Primary Objective: Overall Response Rate Patients scanned (CT) every 2 months and tumour size assessed PART A PART B Dose escalation to Single arm, non-blinded select dose for Part B Simon 2-Stage design 3 p
Slide 8: Analysis by Independent Review
8 Analysis by Independent Review Independent review is Performed by specialist contract organisations 2 independent experts Blinded to initial assessment and blinded to patient clinical data Preferred by regulators in open-label single arm trials Previous data Investigator read Needed in real time t
Slide 9: Additional Complete Responses by Independent Review
9 Additional Complete Responses by Independent Review 400 mg dose PART A PART B 1 CR 4 CR 1 Complete Response 4 Complete Responses 2 Partial Responses 16 Partial Responses (incl. 1 pCR) * Previously reported 1 CR and 1 pCR (investigator read)
Slide 10: ACCENT Pancreatic Cancer Trial Part B
10 ACCENT Pancreatic Cancer Trial PART B ACCENT Trial MPACT Trial (Narmafotinib + G/A) (G/A) CR 7% (4) 0.2% PR 29% (16) 23% SD 33% (18) 27% PD 9% (5) 20% NE 22% (12) 30% ORR 36% (20) 23%
Slide 11: ACCENT Pancreatic Cancer Trial Overall Survival
11 ACCENT Pancreatic Cancer Trial Overall Survival 12 11.1 10 9.2 8 8.5 Months 6 4 2 0 Narmafotinib + G/A G/A (MPACT) G/A (NAPOLI 3)
Slide 12: No Additional Safety Burden to Patients
12 No Additional Safety Burden to Patients Adverse Events (Grade 3 or above) Narmafotinib +Gem/Abr Gem/Abr Gem/Abr NALIRIFOX Adverse Event (AE) Grade ≥ 3 (ACCENT; N=55) (MPACT; N=421) (NAPOLI 3; N=379) (NAPOLI 3; N=370) Neutropenia 38.2% 38% 39% 14% Anemia 9.1% 13% 18% 11% Diarrhea 5.5% 6% 5% 20% Pe
Slide 13: The ACCENT Trial: Improving treatment options for metastatic pancreatic cancer
13 The ACCENT Trial Improving treatment options for metastatic pancreatic cancer Overall Response Overall Survival Safety More patients with complete Patients survive longer than Minimal 5 disappearance of tumour and metastases 1.3x if taking the chemotherapy alone Additional safety burden to the pa
Slide 14: Opportunities: Overcoming other difficult-to-treat cancers
14 Opportunities Overcoming other difficult-to-treat cancers Cancers Combinations Pancreatic Chemotherapies Head and Neck New Targeted Drugs Colorectal FAK Lung Radiation Gastric Antibodies Breast ADCs Ovarian Cell Therapies Liver
Slide 15: Conference Presentation
15 Conference Presentation Further analysis currently underway Planned completion by the AACR Annual Scientific Meeting Oral Presentation 21 April 2026
Slide 16: Key Milestones
16 Key Milestones Upcoming events Ovarian Cancer Trial Commences (potential) Phase 2b/3 AMPLICITY Part B Pancreatic Cancer Completion AMPLICITY Trial Commences Part B commences 2026 2027 2028 2029 ACCENT Trial Data Licensing Regional Licensing or Partnering Deal or Partnering Deal
Slide 17: Thank You
Thank You Chris Burns PhD GAICD FAHMS Rhiannon Jones PhD GAICD CEO and MD COO [email protected] [email protected] Amplia Therapeutics Limited ASX: ATX | OTCQB: INNMF [email protected] ampliatx.com 17
Amplia Therapeutics — Investor Presentation (March 2026) on 6ix